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The pathogenesis of Crohn’s disease (CD) is not entirely understood due to the 
variety of clinical presentations and its multi-factorial nature. It has been determined that 
there is a genetic component to the pathogenesis of the disease, however, the number of 
genes implicated is large and no single genetic mutation has been identified in affected 
individuals. Despite these facts, this thesis aims to elucidate a better understanding of one 
gene of interest, NOD2/CARD15, in the pathogenesis of CD by looking at mutations 
across different affected populations. 
The inclusion of a case study illustrates the possible presentation of Crohn’s 
disease, focusing on certain aspects of diagnosis, treatment, and symptomology. While it 
does not speak to the genetics of the disease, as this is often not determined, it does 
demonstrate the gravity of the disease and the need for definitive answers in determining 
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Inflammatory bowel disease (IBD) is a chronic, idiopathic inflammatory disease 
of the gastrointestinal tract. It is one of the few gastrointestinal and nutritional diseases 
that affects the developed world. There are two main forms of IBD: ulcerative colitis 
(UC) and Crohn’s disease (CD). Crohn’s disease is believed to be caused by the 
imbalance of proinflammatory and anti-inflammatory cytokines. The cause of this 
imbalance is currently debated with explanations ranging from bacterial infection and 
environmental causes to genetic mutations. This paper will discuss the many theories 
surrounding the pathogenesis of CD, treatment options, and the novel findings of the 
susceptibility gene NOD2/CARD15 with the aims of hoping to reach a better 
understanding of its role in the pathogenesis of CD at the molecular level. 
 
Clinical features 
Crohn’s disease is an inflammatory disease that can affect any part of the GI tract.  
The variability in location of disease, intensity of inflammation, and presence of 
extraintestinal complications make the clinical presentation of CD potentially different 
across many patients. Thus, a delayed diagnosis after presentation of symptoms often 
occurs. However, with increased technological advancements in diagnostic procedures, 
this delay has become shorter, though not eliminated (Medscape). 
In 1932, Burrill B. Crohn, M.D. was the first to identify Crohn’s disease. The 
patients he observed presented with a mass in the right iliac region, evidences of fistula 
formation, emaciation and anemia, scar of a previous appendectomy, and evidences of 
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intestinal obstruction. These observations hold true today in diagnosing Crohn’s disease 
(Crohn, 1932). 
CD typically presents with low-grade fever, prolonged diarrhea, abdominal pain, 
weight loss, and general fatigue. Oftentimes, patients also suffer from symptoms of 
intestinal obstruction. This can be due to chronic narrowing of the bowel lumen due to 
inflammation or compacting of undigested foods. Physical examination will often reveal 
the obstruction and subsequent pain. Sometimes the pain can present as if patient has 
appendicitis. Due to the pain experienced when eating, patients often suffer from 
malnutrition and weight loss (often due to anorexia (Feldman, 2010). 
Patients with colitis (rather than ileal inflammation) often present with diarrhea as 
the main complaint. Sometimes blood is also found in the stool. Most do not have 
proctitis because the rectum is spared from inflammation, but this is not always the case. 
While inflammation usually occurs in the small and large intestine, Crohn’s 
disease sometimes manifests in the gastroduodenum and esophagus. Controversy 
continues to surround the diagnosis of Crohn’s in the appendix. As mentioned before, 
Crohn noticed that many of his patients had undergone previous appendectomy before 
manifestation of CD. This increased risk for CD after an appendectomy was recently 
noted but without implication of a cause or simply a correlation (Anderson et. al. 2003). 
A couple theories aim to explain this correlation. One is that appendicitis presents as an 
initial manifestation of CD. In other words, the inflammation presented in the appendix is 
of the same origin as that of intestinal CD. It is difficult to differentiate between 
appendicitis and CD simply because both present as inflammation. There is also likely a 
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diagnostic bias present because appendicitis and CD can be so closely related, with 
patients suffering from similar symptoms. 
Unusual presentations of CD are those that manifest extraintestinally due to 
complications. It is estimated that 6 – 25% of patients present with some sort of 
extraintestinal manifestation (EIM) of the disease. The most common EIMs are arthritis, 
erythema nodosum, episcleritis, and anemia. All are caused by overproduction of 
inflammatory cytokines, and subsequent increase in inflammation. Other EIMs involve 
hepatobiliary, renal, and genitourinary systems (i.e. gallstones) and can also involve other 
systems (resulting in symptoms ranging from vasculitis to glomulonephritis). It is clear 
that the EIMs are caused by the spreading of inflammation. 
Unfortunately, the pathogenesis of EIMs is not entirely understood (Ardizzone, 
2008) (Danese, 2005). However, it is likely that the influx of mononuclear cells activated 
in the intestine homes aberrantly to extraintestinal organs in the body. This mechanism is 
not well understood but would explain the presentation of EIMs in CD patients. 
Interestingly, those with colonic CD are found to have more EIMs than those with ileal 
CD (Greenstein, 1976). This difference is likely due to the difference in gut flora between 
the two areas of the GI tract, which may alter the pathophysiology of the disease. This 
observation would also further implicate the travelling of activated mononuclear cells in 
the intestine as perhaps the colon’s vasculature or gut flora would encourage EIM 
genesis. 
Further complications result in perianal disease. Fissures, fistulas, abcesses, and 
skin tags are among the most common symptoms. The pathogenesis of the fistulas in CD 
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is unknown. However, it is possible that because fistulas usually occur when CD persists 
untreated, translocating bacteria is involved.  
Upon intestinal examination, early findings include apthous ulcers and 
granulomas (upon biopsy). Later findings include the definitive cobblestone appearance 
and deeper ulcerations. These findings are identified using a scope. Further, structuring 
can occur due to prolonged inflammation. Stricturing can be observed using an x-ray, 
where the strictured tract appears like a string on the x-ray. Strictures must be dealt with 
carefully during surgery because they can harbor cancers. 
 
Figure 1: Cobblestone appearance of the ileum typical of Crohn’s disease (Jung, 2010) 
 
Pathophysiology/pathogenesis 
The activation of the adaptive immune response is critical to the pathogenesis of 
Crohn’s disease. Whether this activation is due to an overactive response to normal gut 
flora, a benign molecule, or a specific pathogen is where information becomes limited. 
There is no true evidence of what initiates the response, however, lately there has been 
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great discussion regarding Mycobacterium avium subspecies paratuberculosis (MAP) as 
a potential pathogen activator. 
MAP was first found in animals with Johne’s disease, a disease very similar to 
Crohn’s disease with similar lesions. It has been proven to cause Johne’s disease in 
animals, which led many to believe that MAP would do something similar in humans: 
cause Crohn’s disease. 
MAP DNA was found in disease tissue in 1992, which nearly implicated its 
involvement in Crohn’s disease (Sanderson, 1992). This discovery was highly 
controversial as MAP is also found in pasteurized milk. However, the strongest case 
against MAP causing Crohn’s is that CD patients respond positively to corticosteroids. If 
the disease were entirely bacterial, then an immunosuppressant would worsen symptoms 
of the disease. It is most likely that the organism potentiates the disease (Sartor, 2006). 
Another theory that explains the observations is that there is a TH1 response to 
MAP that leads to chronic inflammation (Byun, 2012). While this doesn’t implicate MAP 
as a causative agent in Crohn’s, it indicates that it is involved in perpetuating 
inflammation. The largest issue in determining if MAP causes CD (in genetically 
susceptible persons) is that introducing the bacteria to these people to see whether or not 
they develop CD is not a great idea. While it would more than likely definitively 
determine MAP’s involvement in CD, it could potentially result in numerous people 
developing a detrimental disease (Huang, 2009). Currently, possibilities of treating and 
controlling Crohn’s disease with antibiotic therapy targeted to MAP are being pursued 




Figure 2: Visual overview of the pathogenesis of CD from Sleisenger and Fordtran’s 
Gastrointestinal and Liver Disease, 9th ed. Edited by Mark Feldman, MD (2010). 
 
Paneth cells (granulated epithelial cells involved in CD pathogenesis) are 
normally found in the ileum and not in the colon. However, with the ileitis or colitis, they 
are found to be in high number in the former and present in the latter. This presence 
indicates a link between Crohn’s and these unique cells. Parasitic infections are usually 
found to induce a high number of Paneth cells. This upregulation can be explained by the 
presence of alpha-defensins, with broad spectrum antimicrobial ability (Grimm, 2004). 
The interaction of effector T cells with antigen presenting cells is important to the 
pathophysiology of Crohn’s disease. Activation of the T cells (by dendritic cells) results 
in release of many cytokines. Of importance is IL-2, which stimulates growth of T cells. 
Further IL-23 and IL-12 are released, which call both TH17 and TH1 responses. 
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The role of Treg (T regulatory) cells in IBD and colorectal cancer has been 
recently studied. Because Treg cells are important in immunological self-tolerance, the 
number of cells present may alter the intestinal mucosa and subsequently the pathogens 
harbored in the area. (Muzes 2012). IL-6 and IL-21 are found to be in high levels in CD 
patients. These cytokines inhibit FoxP3, a transcription factor that encourages the 
development of Treg cells. Therefore, with that inhibition, TH17 cells are further 
recruited, which recruit neutrophils. The abundance of these cells encourages 
inflammation and the utilization of the adaptive immune system. 
There are other pathways that are involved in the progression of CD. 
Unfortunately, due to the idiopathic nature of CD, their involvement is not entirely 
understood. However, some pathways of importance are the IL-23 pathway (which 
mediates the recruitment of TH17 cells) and the autophagy pathway (which is involved in 
bacterial clearance). These pathways are related and work with the initial inflammatory 
pathway. 
While the pathophysiology of Crohn’s disease has been greatly studied, the 
etiology is still unknown. However, understanding the response has resulted in treatments 
to control inflammation and subsequent symptoms. But ultimately, understanding the 
etiology will lead to better treatment options and eventually a cure. 
 
Pathophysiology of symptoms 
The presence of the following symptoms are useful in diagnosis of CD: diarrhea, 
abdominal pain, weight loss and malnutrition, fever, anemia. All these symptoms can be 
explained pathologically in the framework of CD. Diarrhea is often seen in CD patients 
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due to altered intestinal motility. Abdominal pain is not well understood, but often arises 
due to intestinal blockage. Additionally, inflammation of the intestinal walls often also 
induces pain. 
Weight loss and malnutrition are observed because eating frequently causes pain. 
This discourages patients from eating, as their anxiety is accentuated by social situations. 
Patients also suffer from malnutrition mainly as a result of the decrease in eating but also 
from malabsorption due to presence of strictures and ulcerations. Fever, if present, is low-
grade and due to the production of proinflammatory molecules. Finally, anemia related to 
the malnutrition previously discussed is often present. Malabsorption of nutrients such as 
Vitamin B12 and folate are the main causes of megaloblastic anemia; malabsorption of 
iron can cause microcytic anemia. Additionally, overproduction of proinflammatory 
molecules can lead to anemia resistant to iron supplementation (due to inhibited 
erythropoietin production) (Weiss, 2010). Understanding these symptoms and their 




The epidemiology of Crohn’s disease reveals information that can be used in 
understanding the pathogenesis of the disease. Males and females are equally affected by 
CD, which indicates that hormonal or occupational influence is not likely to play a large 
part in the pathogenesis of the disease. Most research indicates that those affected with 
Crohn’s disease are from developed countries, which implicates an environmental factor 
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in the development of CD. Further, there is a growing presence of Crohn’s disease in 
populations that are newly developed (i.e. Asian countries). 
Another interesting aspect of the epidemiology of CD is that there exists a 
bimodal distribution among the affected population when looking at age. The two 
populations most affected are young adults (18-25) and older generations (55+). Older 
patients tend to be diagnosed with colonic and distal Crohn’s disease, whereas younger 
patients have predominantly ileal Crohn’s disease. 
This bimodality likely indicates that there is something in the anatomy of the 
ileum and colon that differs to prefer the manifestation of CD preferentially in some 
populations. The flora present likely directs the formation of CD in a certain area of the 
gut. Additionally, the presence of Paneth cells in the ileum likely explains a preferential 
disease location in individuals with NOD2/CARD15 mutations. But perhaps more 
importantly, the treatment of the different populations is significant, as their course of 
treatment may differ. Older patients often suffer more from immunosuppressant drugs, as 
their immune systems are often already compromised. Further, the observation of 
bimodality with paired difference in disease location calls for further research in 
comparing ileal and colonic Crohn’s disease.  
 
Genetics 
Many genes have been implicated as susceptibility genes for CD. Because 
Crohn’s disease has been identified mostly in individuals who contain these susceptibility 
genes, it is believed that CD is caused by a microbial imbalance in the GI tract in 
individuals who are genetically susceptible to manifestation of the disease. 
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Familial clustering of Crohn’s disease was the first indication that CD was 
genetically based. But further, twin studies have illustrated the importance of genetics in 
Crohn’s disease. A twin study revealed that, in the Danish population, monozygotic twins 
with IBD/CD had 63.6% concordance and dizygotic twins only 3.6% concordance for 
mutations in NOD2/CARD15, a gene implicated CD susceptibility (Jess, 2005). While 
there is a strong indication that genetics are involved, because it is not 100% 
concordance, it is evident that genetics are not completely responsible for the 
development of Crohn’s (Halfvarson, 2005). After the discovery of NOD2/CARD15 as a 
susceptibility gene, specific mutations have been discovered to vary across different 
populations. It is this novel finding that has encouraged the study of the genetics of CD. 
The first gene implicated in the genesis of Crohn’s disease was the 
NOD2/CARD15 gene (Ogura, et. al. 2001). Normally, bacterial peptides bind to NOD-2, 
which are activated and result in an inflammatory response. However, mutations in 
NOD2/CARD15 usually result in defected NOD-2 proteins. Thus, without 
bacteria/bacterial peptide binding, there is no NF-κB response. This lack of response 
likely results in a more severe inflammatory response in dealing with the bacteria, as NF-
κB (innate immunity) is not activated. 
IL-23 is another pathway theorized to be involved in the genesis of Crohn’s 
disease. This pathway is affected genetically as indicated by the genetic mutations of 
IL23R correlated to CD (Barrett, 2008). IL-23 is an important cytokine in stimulating TH1 
cells, and subsequent overproduction can result in increased inflammation. There are 
many other genetic mutations that affect the genesis of CD similarly. 
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The potential for gene therapy at this point seems extremely difficult due to the 
numerous genes implicated in the contribution to the development of CD. However, 
understanding in the perspective of symptoms and potential environmental factors may 
lead to a better understanding of the genetics of and potential therapies for CD.  
 
Figure 3: Differences of genetic variants across European and Asian IBD populations 
from Ng, et. al. (2012). 
 
Environmental factors 
Certain bacteria have been theorized as possible causative agents of Crohn’s 
disease. As discussed previously, MAP is one that is debated. Studies have pointed to 
three bacterial theories, which have yet to be disproven: the unidentified persistent 
pathogen theory, the excessive bacterial translocation theory, and the dysbiosis theory 
(Hertogh, 2008). Further, the involvement of bacteria in the pathogenesis of Crohn’s has 
sparked debate over the “hygiene hypothesis.” Because the disease is mostly found in the 
upper class, it is possible that this hypothesis has some weight. 
12 
 
The populations affected by Crohn’s also indicate that there is an environmental 
influence in the genesis of the disease. There is a significantly higher prevalence of CD in 
developed countries, which some argue indicates that certain bacteria types are more 
likely to initiate an inflammatory response. 
Interestingly, the regional representation of CD affected population reveals a 
significant pattern (Schultz, 2012). There is a higher prevalence of CD in the more 
northern areas of Europe. To confirm a possible geographic distribution, it was also 
observed that the more Northern areas of the US, a more diverse nation that those of 
Europe, also had similar increased rates of CD (Khalili, 2011). This geographic 
observation could point to the role of Vitamin D in the pathogenesis of Crohn’s disease. 
Because people living more northern areas receive less sunlight, and therefore less 
vitamin D, there is a correlation between vitamin D deficiency and CD (Ananthakrishnan, 
2012). Vitamin D decreases TH1 and therefore inhibits secretion of IL-2, IFN-gamma, 
and increase Treg. Perhaps this is just a general immunological effect rather than a 
pathogenesis of Crohn’s. However, it may be useful to implement vitamin D 
supplementation in treatment regimens to determine if it has an effect. 
Smoking has also been implicated in increasing the risk of developing Crohn’s. 
Interestingly, this also alters the location of inflammation. CD patients who smoke are 
more likely to develop Crohn’s in the small intestine over the colon. However, it has been 
difficult to determine if smoking directly contributes to the genesis of CD. It has not been 
determined if the biological interactions of cigarette smoke/byproducts interact with 
genes to result in a mutation (Aldous, 2011) or if those who smoke are predisposed to 
something, which correlates to a susceptibility in developing CD. 
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One aspect of CD has been confirmed: there are more surgeries associated with 
smokers who have CD compared to nonsmokers who have CD (Lindberg, 1992). There is 
a correlation. Further, the immunosuppressive effects of nicotine are well known, which 
indicate a stronger potential involvement of smoking in CD development. Some argue 
that there is a direct differential gene expression as a result of smoking, which leads to 
altered mucosa (Nielsen, 2009). Others have discovered that there is a lower than 
expected correlation between smoking and NOD-2 mutations (Helbig, 2012). It still 
remains unknown whether or not smoking is involved in the genesis of the disease. But it 
is important to note that cessation of smoking has resulted in reduced frequency of 
surgery and more controlled flareups (Mahid, 2006). 
Other questioned environmental factors include stress and NSAID use. Stress is 
often associated with relapse, which warrants the management of it to be included in 
treatment. NSAIDs increase permeability of the gut, which could contribute to IBD. 
However, not much research has been found to support this hypothesis. 
 
Diagnosis 
The similarity of Crohn’s disease to ulcerative colitis makes it difficult to 
diagnose either. Focusing on the following differences allows for the correct diagnosis: 
site of inflammation, complications associated with symptoms, ulcerations, and patterns 
of inflammation. The site of inflammation is the first cue as to whether a patient likely 
has Crohn’s over ulcerative colitis. While Crohn’s can present anywhere within the 
digestive tract (with the small intestine and colon being largely the most frequent areas of 
presentation), ulcerative colitis is generally restricted to the colon. 
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Another distinguishing symptom of CD is the extraintestinal manifestation of the 
disease. Not only does CD affect the GI tract, complications can arise that result in the 
presentation of extraintestinal lesions. Common distinguishing dermatological 
extraintestinal manifestations include erythema nodosum and pyoderma gangrenosum. 
Additionally, joints and eyes are often affected, which provide another diagnostic 
opportunity (Barreiro-de-Acosta, 2012). 
Finally, the patterns of ulcerations are a clue to differentiating between the two 
IBDs. In CD, the ulcerations are often deeper than those found in patients with UC. 
Additionally, the pattern of inflammation is patchy compared to the continuous 
inflammation found in UC. Additionally, biopsy usually reveals granulomas in CD 
patients and not UC patients. 
When IBD is restricted to the colon, it becomes necessary that the differentiation 
between Crohn’s and UC is heavily dependent on examination of the intestines, which is 
an invasive procedure involving endoscopes. Fortunately, recent technology has resulted 
in the development of the SBCE camera, which is swallowed by the patient and used to 
observe the intestines. Often, the distinguishing feature between Crohn’s and UC is the 
presence of skip lesions, or a cobblestone appearance of the GI tract. The cobblestone 
appearance is indicative of Crohn’s disease. 
Treatments for Crohn’s disease are often similar if not identical to that of UC. 5-
aminosalicylic acid (5-ASA) is often the first step in treating both Crohn’s and UC. 
Further, dietary changes become similar and for both diseases are there similar surgical 
procedures in place for treatment. This often makes it seem unimportant in differentiating 
the two diseases. However, understanding the differences between the two will ultimately 
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improve treatments of both. Because UC isn’t based on a TH17 response, it is apparent 
that the most effective treatments for the two diseases will eventually differ. Thus, 
distinguishing between the two diseases is crucial to the effective treatment of both 
individually. 
 
Treatment of Crohn’s disease 
The treatment of inflammatory bowel diseases most often involves the treatment 
and management of symptoms rather than the curing or treatment of the disease. In 
Crohn’s disease the management and control of flare-ups by altering diet is the most 
prescribed treatment.  
Because many CD patients alter their diet to reduce incidences of flare-ups, it is 
important to ensure that the proper nutrients are still being provided in the diet (whether 
by supplementations or substitutions in diet). For example, many CD patients are also 
lactose intolerant. Therefore, it is important to make sure that they are receiving enough 
calcium in their diet. 
Another dietary aspect of CD symptoms treatment is nutrigenomics, the analysis 
of the effect diet has on genes. It is still widely debated but there has been some evidence 
of treatment possibilities. The main premise is that certain foods can induce/reduce the 
expression of certaizymn genes. Research has been done that is promising in overcoming 
the point mutations found on NOD2/CARD15 (Philpott, 2007). 
There are a number of pharmaceutical options to the treatment of Crohn’s. 
Physicians often use a “step-up” approach to treating CD pharmacologically. For mild 
CD, 5-aminosalicylic acid (5-ASA) is used along with antibiotics and nutritional therapy. 
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A step up from this would be the use of 6-MP/azathioprine (Imuran) and methotrexate. 
Using immunosuppressant drugs, the overall symptomology generally clears up in 
patients, however, the use of immunosuppressants leaves patients in a more 
immunocompromised state, a drawback to steroid treatment. This is especially considered 
in older patients who can potentially suffer greatly from this increased risk of infection. 
Antibiotic treatments have not yet been perfected due to the unknown nature of 
the bacteria plaguing the GI tract. However, MAP antibiotics appear to be promising. 
Treatment of extraintestinal manifestations often overlaps with treating CD. 
Either through similar mechanisms or ridding the original cause of the EIMs, treatments 
for EIDs are quite effective. For example, infliximab, a TNF-alpha inhibitor, is used to 
treat both CD and subsequent anemia. While IV iron (oral iron induces flare-ups or is 
destroyed by the GI system) often treats anemia, use of a TNF-alpha inhibitor 
(immunosuppressant) is often just as successful (Bergameschi, 2010). In the case of 
anemia, because Fe absorption is often disrupted by inflammation, the use of a TNF-
alpha inhibitor is likely a more viable option, though not approved yet. 
Similarly, immunosuppressants (e.g. etanercept and adalimumab) are also used to 
treat arthritis, which is a common EIM of CD. Again, the drawback of using 
immunosuppressants is that patients will be more susceptible to developing infections. 
In severe cases, patients undergo bowel resections. But often, the best treatment is 
surgery. After surgery, however, it is imperative that patients maintain their flare-ups and 
ensure that they do not further damage what has been damaged, as their risk of 
developing symptoms requiring surgical intervention increases. 
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Understanding the genetics of Crohn’s disease will help in numerous facets in 
understanding CD. First, it will provide a better understanding in the pathogenesis of CD. 
This understanding will then promote the development of more effective treatments of 
CD, targeting specific pathways involved in the pathogenesis of CD. Hopefully by 
examining the current genes implicated in the development of Crohn’s disease, possible 
treatments (genetic or otherwise) can be explored. 
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 NOD2/CARD15 involvement in the pathogenesis of Crohn’s disease 
 
 While the etiology of Crohn’s disease (CD) remains unknown, it is known that 
genetics plays an important role in the development of the disease. However, it is still not 
completely understood how genetic mutations specifically lead to the development of CD 
and also which genetic mutations are the most involved in developing the disease. 
Additionally, the variability across different ethnic and age groups makes the 
pathogenesis of the disease even more puzzling. The aim of this chapter is to examine the 
NOD2/CARD15 gene to better understand how certain mutations can lead to the 
pathogenesis of CD. Examining various mutations of NOD2/CARD15, their prevalence in 
certain ethnic and age groups, and their effect on the NOD2 protein should reveal 
important mechanisms in the genesis of CD. Thus, the responsibility of this gene in the 
genesis of CD can hopefully be revealed and subsequent treatments can be tailored to this 
disease pathway. 
 NOD2/CARD15 was the first gene to be implicated in the development of Crohn’s 
disease (Ogura, 2001). NOD2/CARD15 codes for NOD2 proteins, which are involved in 
the recognition of bacterial pathogens. The NOD2 protein is involved in the immune 
system, serving to protect against bacterial pathogens. This cytosolic protein is found 
mostly in APCs and intestinal epithelial cells, notably in the Paneth cells of the small 
intestine. The expression of NOD2 is regulated by inflammatory cytokines, with tumor 
necrosis factor (TNF) upregulating its expression (Strober, 2006). 
NOD2 proteins consist of two caspase-recruiting domains (CARD), a nucleotide 
binding domain (NBD) and a leucine-rich region (LRR) that has ten leucine-rich repeats. 
The CARDs are believed to be involved in NF-κB activation, as they are involved in 
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RICK/IKK pathway, which turns on the NF-κB pathway. The NOD also is involved in 
NF-κB activation, but through the binding of nucleotide. Finally, the LRRs are important 
as well, as they are responsible for detecting molecules of pathogenic bacteria (much like 
how LRRs on toll-like receptor proteins detect PAMPs). (Strober, 2006) 
 
Figure 4: Explanation of NOD2 pathway from Strober, 2006 
 
 NOD2 proteins detect muramyl dipeptide (MDP), a bacterial ligand present on 
most bacteria, via their LRRs (Inohara, 2003). Upon MDP-LRR binding, the NOD2 
protein is activated, which then recruits (RICK) through CARD-CARD interaction. RICK 
then polyubiquinates the IKK complex, which is an inhibitor of NF-κB production. 
Subsequently, NF-κB activation occurs, which induces the transcription of inflammatory 
genes. This process occurs normally as the innate immune response against bacteria.  
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 The disruption of the NOD2 pathway has been determined to be involved in the 
pathogenesis of Crohn’s disease, especially due to the genetic evidence present. It has 
been agreed that a defective NOD2 protein will result in decreased or impaired MDP-
LRR binding. Essentially, the NOD2 protein no longer can detect the presence of 
bacteria. Thus, the NF-κB pathway is not activated. Subsequently, the bacteria can 
infiltrate intestinal epithelium and cause a more violent inflammatory response mediated 
by the adaptive immunity, thus, causing chronic inflammation in the GI tract.  
The insertion of a cytosine on exon 11 of chromosome 16q12 (or NOD2) at 
nucleotide 3020 (referred to as 3020insC or 1007fs) resulted in a frameshift mutation and 
resulting truncated LRR of NOD2. The LRR is where bacterial peptides bind to the 
NOD2 protein. Upon binding, NOD2 proteins are activated and result in an inflammatory 
response. Thus, without bacteria/bacterial peptide binding, there is no NF-κB response. 
This lack of response likely results in a more severe inflammatory response in dealing 
with the bacteria, as NF-κB (innate immunity) is not activated. T-cell interaction is 
important in development of Crohn’s, which explains how the NOD2/CARD15 gene 
mutation results in overactive inflammation. 
 
Figure 5: Diagram of the gene and genetic mutations outlining the regions of 





Figure 6: Comprehensive diagram of NOD2/CARD15 gene and genetic mutations from 
Sugimura (2003) 
 
 In addition, two other mutations of the NOD2/CARD15 gene have been associated 
with the development of CD: R702W, G908R. These two base substitution mutations are 
also present on the LRR region of the NOD2 gene, thus altering the LRR region of the 
NOD2 protein (Figure 5). As expected, these two mutations damage NOD2 less than the 
1007fs mutation, given the nature of point mutations. Cuthbert et. al. determined that 
these three mutations of NOD2/CARD15 are significantly present in patients with CD and 
not UC, further implicating them as CD susceptibility genes. Additionally, Cuthbert et. 
al. postulated based on their findings that these NOD2 mutations may result in 
preferential development of CD in the ileum over the colon. For a number of reasons, this 
seems probable: the ileum may rely on NOD2 to deal with bacteria more than the colon 
because the colon has higher concentration of gut flora. Additionally, the presence of 
Paneth cells in the ileum, and their involvement with presenting NOD2 proteins, would 
likely explain why most NOD2 mutations cause ileal disease. 
3020insC was found in many individual with Crohn’s disease, thus indicating a 
correlation between the two. The genetic mutation was found in 17% of the population 
with Crohn’s while the same genetic mutation only existed in about 1% of unaffected 
individuals (Hugot, 2001). Interestingly, this mutation has been shown to be irrelevant in 
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Asian populations, where the incidence of Crohn’s is recent and rapidly rising 
(Yamazaki, 2004).  
Childhood-onset of CD and 3020insC are strongly correlated (Gazouli, 2010). 
This is consistent with the known pathogenesis of the disease and the fact that the 
frameshift mutation results in a more severe disruption of NOD2 bacterial MDP 
recognition. Additionally, this mutation has a correlation with increased need for surgery 
(Tsianos, 2012). Perhaps considering surgery earlier in patients who have this genetic 
mutation will help treatment. 
R702W has been implicated as a susceptibility mutation diminishing the ability to 
activate NF-κB (Bonen, 2003). It is most attributable in non-Jewish whites (see Figure 7) 
and is found commonly in adults. Interestingly, the disease location is more commonly in 
the jejunum and often presents granulomas (Russell, 2005). With this, there is also an 
increased incidence of surgery (Russell, 2005). R702W is not found on the LRR (or other 
functional region), which may contribute to why it is not as detrimental. 
Another missense mutation identified with increased susceptibility is G908R. It 
similarly diminishes ability to activate NF-κB but is found more commonly in Ashkenazi 
Jews (Bonen, 2003). An interesting aspect of this mutation involves smokers, as they 
markedly have a higher incidence of this mutation (Mardini, 2005). This mutation 
subsequently could explain the gene-environment interaction so integral to CD. Because 
nicotine causes immunosuppression, it is possible that this could also explain why the 
disease is often more penetrating in individuals with this mutation (Arnott, 2004) and 
how smoking can exacerbate or possibly even cause CD. Further, this mutation often 
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causes small bowel confinement of CD and stricturing. It is also commonly found in 
children, which may indicate that it causes a more significant pathogenesis than R702W. 
It was found that Asian populations do not have the same NOD2 mutations as 
Caucasians (Leong, 2006). Interestingly, it was found that they have different mutations: 
JW1 (IVS8 +158) and SNP5 (P268S), which are also found to be associated with CD in 
Ashkenazi Jews (Ng, 2012). SNP5 is a mutation is in the NBD (nucleotide binding 
domain), which results in altered signal transduction properties in response to muramyl 
dipeptide (the portion of bacteria that is often detected by NOD2) (Mo, 2012). While this 
mutation has been strongly associated with CD patients, it has not been proven to be 
sufficient enough to cause CD (Chua, 2009). However, it is often found in conjunction 
with those who have the three most common NOD2/CARD15 mutations implicated in 
causation of CD (3020insC, R720W, G908R). 
 





SNP5 was not deemed to be disease causing. Because JW1 was strongly 
associated with SNP5 (and when present with SNP5 found to have highest prevalence of 
CD), it was believed that JW1 would have a role in the disease. The prevalence of JW1 
variant in Malaysians was significant (Ng, 2012), but because the presence of this variant 
also does not cause CD, it is still not known whether or not this variant increases 
susceptibility to Crohn’s or if its presence is indicative of another mutation yet to be 
discovered. 
SNP5 is on the NBD portion of NOD2/CARD15. The NBD domain is necessary 
for activation. After peptide-LRR binding, the NOD2 self oligomerizes to activate. A 
mutation in this region would confer a similar pathogenesis of the disease. However, this 
mutation has also been deemed not significant enough to cause CD (Bonen, 2003). 
The difference between JW1 and other mutations is that it is an intronic mutation. 
This would also explain the presence of JW1 in certain ethnic populations and not others, 
as intronic mutations are highly variable among different ethnic populations. While the 
intronic mutation would likely suggest that gene splicing was variable in polymorphisms, 
it was found that there is not splicing difference between wild types and JW1 mutants. 
Additionally, no DNA binding element sequence (such as a promoter region) was found 
in the polymorphisms (Sugimura, 2003). It is thus likely that the mutation causes a 
difference in expression of protein or alters function. 
Because SNP5 and JW1 are often found associated with each other, it is more 
likely that the two mutations in conjunction can cause disease. Neither mutation can 
cause CD, but together, it would explain the higher incidence of structuring and the 
earlier onset of CD in the patient population. The high prevalence of these two mutations 
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in Jewish and Asian populations would also indicate their possible linkage of the two, 
and that they are likely to cause genesis of CD (Chua, 2009). 
With the larger development of Crohn’s disease in Asia, the genetic differences 
between most Asian and most European/Caucasian populations have been revealed. 
Asian populations (as seen by the Korean population) affected by CD seem to have a 
lower mean age of diagnosis and onset (Prideaux, 2012). The presence of JW1-SNP5 
may be an important indicator of this clinical manifestation. 
Understanding this disease pathway allows us to understand possible ways of 
eliminating disease pathogenesis. Gene therapy seems to be suited to this pathway as a 
genetic mutation causes a misfolded or truncated protein, which results in lack of 
function and eventually pathology. Eliminating the mutations of NOD2/CARD15 would 
conceivably eliminate this disease pathway of Crohn’s disease in populations affected by 
the mutation. 
Some gene therapies currently being pursued involve the regulation of 
inflammatory cytokines rather than direct alteration of NOD2/CARD15. One gene 
therapy involves the upregulation of anti-inflammatory cytokines (IL-10) to quell the 
overinflammation (Wirtz, 2003). Another possibility discussed is the suppression of 
TNF-alpha. This has proven useful in treating arthritis, which is an extraintestinal 
manifestation of CD and therefore will likely have a similar pathophysiological pathway 
that induces inflammation (Kumar, 2005). However, the danger of altering the 
inflammatory cytokines is that regulation is difficult. If TNF-alpha responses were 
reduced via gene therapy, the chances of infection likely would greatly increase, 
26 
 
compared to using immunosuppressant drugs (which can be dosage-modified). Thus, the 
genetic therapy of NOD2/CARD15 is a more attractive approach to treatment. 
The most devastating mutation of NOD2/CARD15 is the frameshift mutation 
1007insC. Frameshift mutations are difficult to repair, as the editing would require either 
an insertion or deletion (in this case, a deletion). While gene therapy would result in the 
best outcomes, it seems infeasible. However, there has been research showing the 
possibility of repairing frameshift mutations using tailed duplex (TD) DNA (Morita, 
2011). Such studies indicate the possibility of repairing mutations, which indicate the 
promise of gene therapy in treating CD. 
The significance of gene therapy is that it allows for personalized medicine. As 
shown previously, this is important in treating CD (via gene therapy) because of the 
various mutations and subsequent pathologies that can present. For example, the only 
mutation with increased presence of granuloma is R702W. This unique symptom would 
call for unique treatment, hence the appeal of personalized gene therapy. Additionally, 
screening for mutations can help with diagnosis and early prevention of disease 
progression since many mutations correlate with earlier onset (i.e. 1007fs), higher 
incidence of stricturing and greater need for surgery (e.g. JW1). 
In conclusion, the impaired function of the NOD2 protein results in the lack of 
NF-κB production. This, counterintuitively, results in the overproduction of 
inflammation, often leading to chronic inflammation. The overproduction of 
inflammatory cytokines is due to the lack of innate immune response via NOD2 proteins. 
As a result, the body counters bacterial pathogens using the adaptive immunity, which is 
a harsher response than the innate immunity, which could have cleared the bacterial 
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pathogens. Additionally, the lack of innate immune response can allow for the migration 
of bacteria into areas of the gut, which will also precipitate a harsh inflammatory 
response. Understanding this pathway is critical in understanding potential treatments of 
Crohn’s disease (i.e. better management of chronic inflammation). Because some patients 
respond better to certain treatments, based on genetic mutations involved in CD 
development, it becomes most important to find personalized treatments. Of these, some 
possibilities have been discussed ranging from gene therapy of NOD2/CARD15 to gene 
regulators of inflammatory molecules. The uniqueness of symptom prevalence in 
different populations with varying mutations indicates the possible need for personalized 
medicine in improving disease treatment and management. Evaluating how patients 






Chief complaint  
Abdominal pain, diarrhea 
History of present illness 
Jason Yang is a 20-year-old Asian male who comes to the clinic with complaints 
of episodic diarrhea and infrequent abdominal pain, which has lasted for the last 5 weeks. 
He reports stabbing abdominal pain that is mostly localized to the lower right quadrant. 
He says these symptoms are similar to his symptoms before his appendectomy, which 
occurred when he was 11-years-old. His symptoms usually appear within 30 min of a 
meal and were the worst two nights ago after eating spicy food. His pain on a scale of 1-
10 was an 8 during the last episode; at best his pain is a 1 (mild discomfort). He took 
Imodium OTC, which resulted in some relief. In an overall attempt to alleviate 
symptoms, Jason has changed his diet over the past 2 weeks by avoiding dairy products. 
He reports that this change has lessened the frequency of episodes from 3-4 times a day 
to 1-2, but diarrhea and abdominal pain still persist. He doesn’t know if wheat/gluten 
products provoke his symptoms. These symptoms are nothing new to Jason (they have 
existed since he was around age 11), but this is the first time since his appendectomy that 
he remembers having symptoms this prolonged and severe.  
His maternal grandmother was diagnosed with IBD in her early 20s and is still 
living. He denies any vomiting, heartburn, or blood in the stool. He also denies distention 
or gas. He complains of fatigue and has noticed unintentional weight loss of about 10 lbs 
over these 5 weeks. Additionally, he reports bilateral blurry vision and eye redness at 
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times, but associates these symptoms with his recent switch to contact lens wear. He 
denies rash and joint pain. 
 
Past medical history 
Jason has been a generally healthy person and eats three meals a day. His diet is 
diverse, but limited in dairy products. He denies any other active problems with his 
health. He had an appendectomy in 2003, but reports no other hospitalizations, surgeries, 
or major illnesses. Additionally, he denies any injuries or accidents and is up to date on 
all his immunizations. 
 
Family history 
Jason is the oldest of two. His younger brother is 16-years-old, is well-developed, 
and is in good health. Both of his parents are alive, in their 50s, and in good health. His 
maternal grandmother was diagnosed with IBD in her early 20s and is still living today. 
His maternal grandfather and paternal grandmother are alive, in their 70s, and in good 
health. His paternal grandfather died from pneumonia at age 71. There is no family 
history of autoimmune disease or colon cancer. Additionally, there is no family history of 
heart disease, diabetes mellitus, or other cancers. 
 
Social history 
Jason is a student working towards a biology degree at the local university. While 
Jason eats three times a day, he does not eat many home cooked meals. As a result, his 
diet is high in carbohydrates and fats. Additionally, he takes daily multivitamins and does 
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not take regularly prescribed medications. Due to his busy schedule, Jason rarely finds 
time to exercise. He reports that he exercises at most twice a week, 30 minutes each time. 
He has never been tested for allergies (food or environmental) nor does he have pets, so 
he is unaware of what he might be allergic to. He further denies ever suffering from an 
allergic reaction.  
Jason also reports that he hasn’t traveled outside the U.S. in the past year. He 
admits that he drinks on occasion, averaging 2-3 beers a week. He denies binge drinking. 
He also denies recreational drug use, including intranasal cocaine use and IV drug use. 
Jason has been smoking since the age of 17. He currently smokes about a half pack a day. 
Regarding sexual history, Jason has been sexually active for one year and has only had 
one partner, his current girlfriend. He reports that he always uses a condom and that he 
and his partner were both tested for STDs three months ago, with negative test results. 
Jason has not been diagnosed with prior STDs. 
 
Review of systems 
General: as per HPI 
Skin: no rashes, skin lesions 
HEENT: (+) b/l blurry vision, (+) b/l redness, wears contacts/glasses, sees eye doctor 
regularly; no hearing loss, sees dentist regularly, no sinus congestion; no lesions present 
on tongue, gums 
Resp: no productive cough; no SOB 
Cardio: no palpitations, no chest pressure 
GI: as per HPI 
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GU: no h/o STD, no urinary symptoms of pain, increased urgency or frequency, no 
sexual dysfunction 
Endo: within normal limits 
Musculoskeletal: no joint pain, redness, swelling 




Vitals: BP: 118/70 HR: 92 Temp: 99.4  RR: 14  O2 sat: 98% 
Height: 64”  Weight: 120 lbs.  BMI: 20.6 
 
General: Sitting comfortably in chair, appears pale and in no distress. Appears to be the 
stated age. 
Skin: No visible lesions or rashes; tattoo left arm 
Lymph: No lymphadenopathy or tenderness of supraclavicular or axillary nodes. 
Head: Skull is symmetrical. No lesions or areas of tenderness. 
Ears: Hearing intact. Tympanic membrane appears intact, grey, and pearly. 
Eyes: Bilateral redness present in sclera. PERRLA. Visual fields are intact. Visual acuity 
is 20/30 left and right corrected. No papilledema on fundoscopic exam. 
Nose: Symmetrical, no lesions and nontender. 
Throat: Mucosa is pink and moist without any visible lesions. Tonsils are small without 
exudates. 
Neck: Neck is supple. Full ROM without tenderness. Normal thyroid.  
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Chest: Symmetrical expansion. Breath sounds are normal. No rales, rhonchi, or wheezes 
present. Normal percussion bilaterally. 
Heart: Regular rate and rhythm. No murmurs, rubs, or gallops. Normal S1 and S2. 
Abdomen: Abdomen is flat. Normal bowel sounds in all quadrants. Mild diffuse 
tenderness with palpation. Increased tenderness in lower right quadrant with palpation. 
No masses. No organomegaly. RLQ transverse scar from appendectomy. 
Genitourinary: Normal circumcised male, no costovertebral angle tenderness 
Rectal: Normal sphincter tone. No hemorrhoids, fistulas, masses present. No 
prostatomegaly. Presence of stool. Stool for occult blood positive. 
MS: Full ROM of all joints. Muscle strength 5/5 for all extremities bilaterally. No 
clubbing, cyanosis, or edema. 
Peripheral Vascular: All peripheral pulses 2+, bilaterally. 
Neurologic: Normal affect. Cranial nerves II-XII are intact. Biceps, triceps, 
brachioradialis, quadriceps, and ankle reflexes 2+/4 bilaterally; pinprick and vibration 
sense are intact in fingers and toes.  
 
Laboratory and imaging findings 
Table 1: Laboratory findings for Jason Yang 
CBC w/ differential/platelet    
Test Result Units Reference 
WBC 12 500 cells/mm3 4 500-11 000 
RBC 3.39 106/µL 4.73-5.49 
Hemoglobin 12.2 g/dL 14.40-16.60 
Hematocrit 37.3 % 42.9-49.1 
MCV 110 µm3 76-100 
MCH 36 pg 27-31 
MCHC 33 g/dL 33-37 
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RDW 14.4  11.5-14.5 
Platelets 398 000 µL 150 000 – 450 000 
Neutrophils 47 % 40-76 
Lymphocytes 42 % 16-43 
Monocytes 8 % 2.0-10 
Eosinophils 2 % 1.0-6.0 
Basophils 1 % <1.0-2.0 
Neutrophils (Absolute) 5.9 103/µL 1.8-7.8 
Lymphocytes (Absolute) 5.3 103/µL 0.7-4.5 
Monocytes (Absolute) 1.0 103/µL 0.1-1.0 
Eosinophils (Absolute) 0.3 103/µL 0.0-0.4 
Basophils (Absolute) 0.1 103/µL 0.0-0.2 
    
Metabolic Panel    
Test Result Units Reference 
Glucose 96 mg/dL 70-105 
Renal function test    
BUN 14 mg/dL 5-20 
Creatine, serum 0.5 mg/dL <1.2 
Electrolytes    
Calcium, serum 8.3 mg/dL 8.2-10.2 
Chloride, serum 90 mEq/L 97-107 
CO2 27 mmol/L 23-29 
Potassium, serum 3.5 mEq/L 3.5-5 
Sodium, serum 131 mmol/L 136-145 
Liver function test    
Albumin 4.1 g/dL 3.5-5.0 
ALP 24 U/L 20-70 
ALT 7 U/L 0-30 
AST 10 U/L 8-20 
Bilirubin 0.8 mg/dL 0.3-1.0 
Total protein 6.1 g/dL 6.0-8.0 
Lipid panel    
Cholesterol 130 mg/dL <200 
LDL 89 mg/dL 50-190 
HDL 38 mg/dL 30-70 
Thyroid test    
TSH 2.4 mU/mL 0.7-5.3 
T3 38 % 30-40 
T4 9 mg/dL 5-12 
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FTI 3.42  6.5-1.25 
    
Additional Serum Tests    
Test Result Units Reference 
ESR 34 mm/h <15 
CRP 16 mg/dL 0-10 
    
B12, Serum 61 pg/mL >100-700 
Folate, Serum 7.2 ng/mL >2.0 
Iron, Serum 69 mg/dL 65-175 
    
tTG-IgA 1.4 U/mL <4.0 
IgA, Serum 210 mg/dL 40-400 
    
Hydrogen breath test    
Lactose breath hydrogen test 11 ppm 10-20 indet. 
Reference values from Gomella, 2002; Curry; Petrany, Mayo Clinic. 
 
 
Figure 8: Peripheral smear morphology (Edward C. Klatt, MD, obtained from WebPath, 
hosted by University of Utah Eccles Health Sciences Library) 
 




Figure 9: Colonoscopy imaging (Paul Rutgerts, MD, PhD, FRCP, obtained from 
UpToDate) 
 
Presence of ulcerations: A) areas of apthous ulcers present; B) large ulcers found, 
interspersed in proximal ileum.  
 
Figure 10: SBFT imaging with Barium contrast (Jonathan Kruska, MD, PhD, from 
UpToDate) 
 
Small bowel follow through examination (with barium) indicates nodular filling 




Figure 11: Biopsy of the ileum (Edward C. Klatt, MD, obtained from WebPath, hosted by 
University of Utah Eccles Health Sciences Library) 
 
Biopsy reveals presence of granulomas, a characteristic diagnostic finding. 
Assessment and differential 
Jason is a 20 yo Asian male presenting with abdominal pain, diarrhea, and fatigue 
for five weeks, unintentional weight loss of 10 lbs., and positive family history for IBD. 
Additional symptoms include acute bilateral eye redness and blurry vision. Physical exam 
reveals mild diffuse abdominal pain, with moderate RLQ pain and the presence of occult 
blood. Lab results reveal leukocytosis, elevated CRP and ESR, megaloblastic anemia and 
vitamin B-12 deficiency. Colonoscopy found aphthous ulcers and cobblestone ulcerations 
in the distal ileum, and small bowel follow-through detected strictures. 
The differential diagnoses for abdominal pain, diarrhea, and unintentional weight 
loss include Crohn’s disease, Celiac disease, ulcerative colitis, lactose intolerance, and 
infectious colitis. The combination of these symptoms with inflammation in the eyes and 
leukocytosis with elevated inflammatory markers points to Crohn’s disease, however, 
other possibilities were considered since Celiac disease can present with extraintestinal 
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manifestations as well. IgA and tTG results were negative, making Celiac unlikely. 
Results of the colonoscopy make ulcerative colitis a less likely diagnosis. The presence of 
aphthous ulcers and cobblestone ulcerations in the small intestine point to Crohn’s 
disease, as small intestine involvement in ulcerative colitis does not usually occur. Jason 
presented with RLQ pain, which is more commonly seen in Crohn’s patients, whereas 
left-sided pain is usually observed in UC patients. Additionally, the ileal involvement, 
confirmed with colonoscopy, could be causing malabsorption and a B-12 deficiency. 
Absence of gas and bloating make lactose intolerance a less likely diagnosis. Lactose 
breath hydrogen test was negative as well. Infectious colitis is also not likely because the 
time course is too drawn out for an infectious agent and the patient has not traveled 
recently. 
The patient is diagnosed with active Crohn’s disease of the ileum with associated 
B-12 deficiency, megaloblastic anemia and possible uveitis. 
 
Plan 
1. Ileal Crohn’s disease 
Due to ileal involvement and abdominal pain, the Crohn’s disease is classified as 
moderate. Prescribed mesalamine 800mg PO tid x 6wk. Advised to keep a diary 
of foods eaten and subsequent symptoms in order to identify trigger foods. Also 
directed patient to research diets that would exclude specific trigger foods. 
2. Megaloblastic anemia/vitamin B-12 deficiency 
Anemia is a pressing issue, making the disease moderate. Cyanocobalamin 100 
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µg IM daily x 1wk, then 100 µg IM every other day x 2wk will be given to the 
patient to eliminate B-12 deficiency.  
3. Possible uveitis 
Advised to discontinue contact lens wear. If no clearance of symptoms, 
prednisolone acetate 1% (ophthalmic susp) 1-2 drops o_2 bid or prn. It is likely 
that uveitis will clear with clearance of Crohn’s. 
4. Prevention 
Smoking cessation was advised, as smoking is strongly correlated with increased 
incidence of flare-ups and episodes in Crohn’s disease. 
Referral to gastroenterologist will be made for management of Crohn’s disease. 
5. Follow-up 
Patient will be seen again in three weeks to evaluate B-12 deficiency and Crohn’s 
disease. It is likely that B-12 deficiency will be cleared with the clearance of 
Crohn’s. If mesalamine is not effective in managing the patient’s Crohn’s disease, 
he will be given budesonide in conjunction with mesalamine. It has been shown 






Aldhous, M. C., Soo, K., Stark, L. A., Ulanicka, A. A., Easterbrook, J. E., Dunlop, M. G., 
Satsangi, J. (2011). Cigarette smoke extract (CSE) delays NOD2 expression and 
affects NOD2/RIPK2 interactions in intestinal epithelial cells. PloS one, 6(9), 1-
15. 
 
Ananthakrishnan, A. N., Khalili, H., Higuchi, L. M., Bao, Y., Korzenik, J. R., 
Giovannucci, E. L., Richter, J. M., et al. (2012). Higher predicted vitamin D status 
is associated with reduced risk of Crohn’s disease. Gastroenterology, 142(3), 
482–489.  
 
Ardizzone, S., Puttini, P. S., Cassinotti, A., Porro, G. B. (2008). Extraintestinal 
manifestations of inflammatory bowel disease. Digestive and Liver Disease, 
40(2), S253–259.  
 
Arnott, I. D. R., Nimmo, E. R., Drummond, H. E., Fennell, J., Smith, B. R. K., 
MacKinlay, E., Morecroft, J., et. al. (2004). NOD2/CARD15, TLR4 and CD14 
mutations in Scottish and Irish Crohn’s disease patients: evidence for genetic 
heterogeneity within Europe?. Genes and Immunity, 5(5), 417–425. 
 
Barreiro-de-Acosta, M., Lorenzo, A., Domínguez-Muñoz, J. E. (2012). Efficacy of 
adalimumab for the treatment of extraintestinal manifestations of Crohn’s disease. 
Revista espanola de enfermedades digestivas, 104(9), 468–472. 
 
Barrett, J. C., Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. 
R., et al. (2008). Genome-wide association defines more than 30 distinct 
susceptibility loci for Crohn’s disease. Nature Genetics, 40(8), 955–962.  
 
Bonen, D. K., Ogura, Y., Nicolae, D. L., Inohara, N., Saab, L., Tanabe, T., Chen, F. F., 
et. al. (2003). Crohn’s disease-associated NOD2 variants share a signaling defect 
in response to lipopolysaccharide and peptidoglycan. Gastroenterology, 124(1), 
140–146.  
 
Byun, E.-H., Kim, W. S., Kim, J.-S., Won, C.-J., Choi, H.-G., Kim, H.-J., Cho, S.-N., et 
al. (2012). Mycobacterium paratuberculosis CobT activates dendritic cells via 
engagement of toll-like receptor 4 resulting in Th1 cell expansion. The Journal of 
Biological Chemistry, 287(46), 38609–38624.  
 
Crohn B. B., Ginzburg L., Oppenheimer G. D. (1932). Regional ileitis, a pathological and 
clinical entity. Journal of the American Medical Association, 99, 1323-1329. 
 
Croucher, P. J., Mascheretti, S., Hampe, J., Huse, K., Frenzel, H., Stoll, M., Schreiber, S. 
(2003). Haplotype structure and association to Crohn’s disease of CARD15 
40 
 
mutations in two ethnically divergent populations. European Journal of Human 
Genetics. 11(1), 6–16. 
 
Cummings, J. R. F., Cooney, R. M., Clarke, G., Beckly, J., Geremia, A., Pathan, S., 
Hancock, L., et al. (2010). The genetics of NOD-like receptors in Crohn’s disease. 
Tissue Antigens, 76(1), 48–56.  
 
Curry, C V, MD. Differential Blood Count. Medscape. 
http://emedicine.medscape.com/article/2085133-overview 
 
Cuthbert, A. P., Fisher, S. A., Mirza, M. M., King, K., Hampe, J., Croucher, P. J. P., 
Mascheretti, S., et. al. (2002). The contribution of NOD2 gene mutations to the 
risk and site of disease in inflammatory bowel disease. Gastroenterology, 122(4), 
867–874.  
 
Danese, S., Semeraro, S., Papa, A., Roberto, I., Scaldaferri, F., Fedeli, G., Gasbarrini, G. 
(2005). Extraintestinal manifestations in inflammatory bowel disease, World 
Journal of Gastroenterology 11(46), 7227–7236. 
 
Das, K. M., & Seril, D. N. (2012). Mycobacterium avium subspecies. Journal of Clinical 
Gastroenterology, 46(8), 627–628. 
 
Gazouli, M. (2010). NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and 
childhood-onset of Crohn’s disease. World Journal of Gastroenterology, 16(14), 
1753-1758.  
 
Gomella, L G, Haist, S A. Clinician’s Pocket Reference, 9th edition. Garden Grove, 
California: McGraw-Hill; 2002. 
 
Greenstein, A., Janowitz, H., Sachar, D. (1976). The extra-intestinal complications of 
Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine, 55(4), 
401–412. 
 
Hertogh, G. De, Aerssens, J., Geboes, K. P., Geboes, K. (2008). Evidence for the 
involvement of infectious agents in the pathogenesis of Crohn’s disease, World 
Journal of Gastroenterolgoy. 14(6), 845–852. 
 
Hugot, J., Chamaillard, M., Zouali, H., Lesage, S., Cezard, J. P., Belaiche, J., Almerk, S., 
et. al. (2001). Association of NOD2 leucine-rich repeat variants with 
susceptibility to Crohn’s disease. Nature, 411, 599–603. 
 
Jung, S.-A. (2012). Differential diagnosis of inflammatory bowel disease: what is the role 




Khalili, H., Huang, E. S., Ananthakrishnan, A. N., Higuchi, L., Richter, J. M., Fuchs, C. 
S., Chan, A. T. (2012). Geographical variation and incidence of inflammatory 
bowel disease among US women. Gut, 61(12), 1686–1692.  
 
Kumar, R., Dammai, V., Yadava, P. K., Kleinau, S. (2005). Gene targeting by ribozyme 
against TNF-alpha mRNA inhibits autoimmune arthritis. Gene Therapy, 12(20), 
1486–1493.  
 
Leong, R. W. L., Lau, J. Y., Sung, J. J. Y. (2006). The epidemiology and phenotype of 
Crohn’s disease in the Chinese population. Inflammatory Bowel Diseases, 10(5), 
646–651.  
 
Mahid, S., Minor, K., Soto, R., Hornung, C., Galadiuk, S. (2006). Smoking and 
inflammatory bowel disease: a meta-analysis. Mayo Clinic Proceedings, 81(11), 
1462–1471.  
 
Mardini, H. E., Gregory, K. J., Nasser, M., Selby, L., Arsenescu, R., Winter, T. A, De 
Villiers, W. J. S. (2005). Gastroduodenal Crohn’s disease is associated with 
NOD2/CARD15 gene polymorphisms, particularly L1007P homozygosity. 
Digestive Diseases and Sciences, 50(12), 2316–2322.  
 
Mayo Clinic. Mayo Clinic Laboratories. Test ID: TTGA. Mayo Foundation for Medical 
Education and Research. http://www.mayomedicallaboratories.com/test-
catalog/Clinical+and+Interpretive/82587 
 
Morita, Y., Tsuchiya, H., Harashima, H., Kamiya, H. (2011). Correction of frameshift 
mutations with tailed duplex DNAs. Biological & Pharmaceutical Bulletin, 34(9), 
1465–1468.  
 
Műzes, G., Molnár, B., Sipos, F. (2012). Regulatory T cells in inflammatory bowel 
diseases and colorectal cancer. World Journal of Gastroenterology, 18(40), 5688–
5694.  
 
Ng, S. C., Tsoi, K. K. F., Kamm, M. A., Xia, B., Wu, J., Chan, F. K. L., Sung, J. J. Y. 
(2012). Genetics of inflammatory bowel disease in Asia: systematic review and 
meta-analysis. Inflammatory Bowel Diseases, 18(6), 1164–1176.  
 
Ogura, Y., Bonen, D., Inohara, N., Nicolae, D. (2001). A frameshift mutation in NOD2 
associated with susceptibility to Crohn’s disease. Nature, 411, 603–606.  
 
Okazaki, T., Wang, M.-H., Rawsthorne, P., Sargent, M., Datta, L. W., Shugart, Y. Y., 
Bernstein, C. N., et al. (2008). Contributions of IBD5, IL23R, ATG16L1, and 
NOD2 to Crohn’s disease risk in a population-based case-control study: evidence 




Petrany, S, MD. Normal Lab Values. Marshall University School of Medicine. 
http://musom.marshall.edu/usmle/usmlelabvalues.htm 
 
Philpott, M., Mackay, L., Ferguson, L. R., Forbes, D., & Skinner, M. (2007). Cell culture 
models in developing nutrigenomics foods for inflammatory bowel disease. 
Mutation Research, 622(1-2), 94–102.  
 
Prideaux, L., Kamm, M. A., De Cruz, P. P., Chan, F. K. L., Ng, S. C. (2012). 
Inflammatory bowel disease in Asia: A systematic review. Journal of 
Gastroenterology and Hepatology, 27(8), 1266–1280. 
 
Rangasamy, P., et. al. (2011). Crohn disease. eMedicine. Retrieved 9 October 2012 from 
http://emedicine.medscape.com/article/172940-overview 
 
Russell, R. K., Drummond, H. E., Nimmo, E. E., Anderson, N., Smith, L., Wilson, D. C., 
Gillett, P. M., et. al. (2005). Genotype-phenotype analysis in childhood-onset 
Crohn’s disease: NOD2/CARD15 variants consistently predict phenotypic 
characteristics of severe disease. Inflammatory Bowel Diseases, 11(11), 955–964. 
 
Sanderson, J. D., Moss, M. T., Tizard, M. L., Hermon-Taylor, J. (1992). Mycobacterium 
paratuberculosis DNA in Crohn’s disease tissue. Gut, 33(7), 890–896.  
 
Sartor, R. B. (2006). Mechanisms of disease: pathogenesis of Crohn’s disease and 
ulcerative colitis. Nature clinical practice. Gastroenterology & Hepatology, 3(7), 
390–407. 
 
Schultz, M., Butt, A. G. (2012). Geographical variation and incidence of inflammatory 
bowel disease among US women. Gut, 61(12), 1686–1692.  
 
Selby, W., Pavli, P., Crotty, B., Florin, T., Radford-Smith, G., Gibson, P., Mitchell, B., et 
al. (2007). Two-year combination antibiotic therapy with clarithromycin, 
rifabutin, and clofazimine for Crohn’s disease. Gastroenterology, 132(7), 2313–
2319.  
 
Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, 9th ed. Edited by Mark 
Feldman, MD. Philadelphia: 2010. Accessed through MD Consult (online). 
 
Strober, W., Murray, P. J., Kitani, A., Watanabe, T. (2006). Signalling pathways and 
molecular interactions of NOD1 and NOD2. Nature reviews. Immunology, 6(1), 
9–20.  
 
Strober, W., Kitani, A, Fuss, I., Asano, N., Watanabe, T. (2008). The molecular basis of 





Sugimura, K., Taylor, K. D., Lin, Y., Hang, T., Wang, D., Tang, Y.-M., Fischel-
Ghodsian, N., et. al. (2003). A novel NOD2/CARD15 haplotype conferring risk 
for Crohn disease in Ashkenazi Jews. American Journal of Human Genetics, 
72(3), 509–518.  
 
Weiss, B., Shamir, R., Bujanover, Y., Waterman, M., Hartman, C., Fradkin, A., 
Berkowitz, D., et. al. (2004). NOD2/CARD15 mutation analysis and genotype-
phenotype correlation in Jewish pediatric patients compared with adults with 
Crohn’s disease. The Journal of Pediatrics. 452(2), 208-212. 
 
Weiss, G., Gasche, C. (2010). Pathogenesis and treatment of anemia in inflammatory 
bowel disease. Haematologica, 95(2), 175–178.  
 
Wirtz, S., Neurath, M. F. (2003). Gene transfer approaches for the treatment of 
inflammatory bowel disease. Gene Therapy, 10(10), 854–60.  
 
Yamazaki, K., Takazoe, M., Tanaka, T., Kazumori, T., Nakamura, Y. (2002). Absence of 
mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn’s 
disease. Journal of Human Genetics, 47(9), 469–472.  
 
